Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation

Collapse authors list.
King, Charlotte ORCID: 0000-0002-7887-3640, McKenna, Amanda, Farzan, Niloufar, Vijverberg, Susanne J, van der Schee, Marc P, Maitland-van der Zee, Anke H, Arianto, Lambang, Bisgaard, Hans, Bonnelykke, Klaus, Berce, Vojko et al (show 26 more authors) , Potocnik, Uros, Repnik, Katja, Carleton, Bruce, Daley, Denise, Chew, Fook Tim, Chiang, Wen Chin, Sio, Yang Yie, Cloutier, Michelle M, Den Dekker, Herman T, Duijts, Liesbeth, de Jongste, Johan C, Dijk, F Nicole, Koppelman, Gerard H, Flores, Carlos, Hernandez-Pacheco, Natalia, Pino-Yanes, Maria, Mukhopadhyay, Somnath, Basu, Kaninika, Bignell, Lauren, Tantisira, Kelan G, Turner, Steve, Verhamme, Katia M, Francis, Ben ORCID: 0000-0002-2130-5976, Pirmohamed, Munir ORCID: 0000-0002-7534-7266, Sinha, Ian and Hawcutt, Daniel B ORCID: 0000-0002-8120-6507 (2020) Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation. , United States.

Text Abstract Pharmacogenomics Conference.docx - Author Accepted Manuscript Download (13kB)

Abstract

A systematic review of pharmacogenomic studies capturing adverse drug reactions (ADRs) related to asthma medications was undertaken, and a survey of Pharmacogenomics in Childhood Asthma (PiCA) consortia members was conducted. Studies were eligible if genetic polymorphisms were compared with suspected ADR(s) in a patient with asthma, as either a primary or secondary outcome. Five studies met the inclusion criteria. The ADRs and polymorphisms identified were change in lung function tests (rs1042713), adrenal suppression (rs591118), and decreased bone mineral density (rs6461639) and accretion (rs9896933, rs2074439). Two of these polymorphisms were replicated within the paper, but none had external replication. Priorities from PiCA consortia members (representing 15 institution in eight countries) for future studies were tachycardia (SABA/LABA), adrenal suppression/crisis and growth suppression (corticosteroids), sleep/behaviour disturbances (leukotriene receptor antagonists), and nausea and vomiting (theophylline). Future pharmacogenomic studies in asthma should collect relevant ADR data as well as markers of efficacy.

Item Type:	Conference or Workshop Item (Unspecified)
Uncontrolled Keywords:	Humans, Anti-Asthmatic Agents, Risk Assessment, Risk Factors, Phenotype, Polymorphism, Single Nucleotide, Adolescent, Adult, Middle Aged, Child, Child, Preschool, Female, Male, Young Adult, Drug-Related Side Effects and Adverse Reactions, Pharmacogenomic Variants, Pharmacogenomic Testing
Depositing User:	Symplectic Admin
Date Deposited:	15 Jul 2019 08:15
Last Modified:	19 Jan 2023 00:37
DOI:	10.1038/s41397-019-0140-y
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3049816